Keyword: Bristol-Myers Squibb
Tsai took up the same position at Amgen 11 months ago but had his head turned by the digitally enabled pipeline Narasimhan is building at Novartis.
The deal gives J&J a stake in the development and commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.
The partners will use Illumina’s NGS capabilities to create IVDs that assess tumor mutation burden and other potentially predictive biomarkers.
The cancer startup says its lead candidate will start a phase 2 trial in rare cancer adenoid cystic carcinoma later this year.
Tempest Therapeutics is chasing Incyte and Bristol-Myers with what it thinks is a best-in-class IDO inhibitor.
Alland landed the role on the strength of a CV that features stints spent at AstraZeneca, Bristol-Myers Squibb and Novartis.
Bristol-Myers Squibb has added Yale Cancer Center to its list of participants in a cancer immunotherapy initiative.
Bristol-Myers is doling out pink slips at an accelerating rate as it gets closer to shuttering by the end of the year.
The takeover will give Merck control of an oncolytic immunotherapy that Viralytics is testing in combination with Keytruda in early-phase trials.
Bristol-Myers is committing $3.6 billion to a deal that gives Nektar most of the profits and freedom to develop the drug in other combinations.